4 Feb 2022

Disposals of own shares

Read More
4 Feb 2022

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Read More
2 Feb 2022

Transparency notification FMR LLC.

Read More
2 Feb 2022

UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[®] (brivaracetam) and VIMPAT[®] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years

Read More
1 Feb 2022

UCB Commences Tender Offer to Acquire Zogenix, Inc.

Read More
28 Jan 2022

Disposals of own shares

Read More
24 Jan 2022

BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma

Read More
21 Jan 2022

Disposals of own shares

Read More
21 Jan 2022

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study

Read More
19 Jan 2022

UCB to acquire Zogenix

Read More
Subscribe to